Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Oligonucleotide therapeutic approaches for Huntington disease.

Sah DW, Aronin N.

J Clin Invest. 2011 Feb;121(2):500-7. doi: 10.1172/JCI45130. Epub 2011 Feb 1. Review.

2.

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.

Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR.

Mol Ther. 2011 Dec;19(12):2178-85. doi: 10.1038/mt.2011.201. Epub 2011 Oct 4.

3.

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.

Fiszer A, Olejniczak M, Switonski PM, Wroblewska JP, Wisniewska-Kruk J, Mykowska A, Krzyzosiak WJ.

BMC Mol Biol. 2012 Mar 7;13:6. doi: 10.1186/1471-2199-13-6.

4.

Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

Gagnon KT, Pendergraff HM, Deleavey GF, Swayze EE, Potier P, Randolph J, Roesch EB, Chattopadhyaya J, Damha MJ, Bennett CF, Montaillier C, Lemaitre M, Corey DR.

Biochemistry. 2010 Nov 30;49(47):10166-78. doi: 10.1021/bi101208k. Epub 2010 Nov 8.

5.

Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.

Evers MM, Tran HD, Zalachoras I, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM.

Nucleic Acid Ther. 2014 Feb;24(1):4-12. doi: 10.1089/nat.2013.0452. Epub 2013 Dec 31.

PMID:
24380395
6.

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.

Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, Hayden MR.

PLoS One. 2014 Sep 10;9(9):e107434. doi: 10.1371/journal.pone.0107434. eCollection 2014.

7.

In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.

Southwell AL, Skotte NH, Kordasiewicz HB, Østergaard ME, Watt AT, Carroll JB, Doty CN, Villanueva EB, Petoukhov E, Vaid K, Xie Y, Freier SM, Swayze EE, Seth PP, Bennett CF, Hayden MR.

Mol Ther. 2014 Dec;22(12):2093-106. doi: 10.1038/mt.2014.153. Epub 2014 Aug 7.

8.

Neurodegeneration. Huntington's research points to possible new therapies.

Marx J.

Science. 2005 Oct 7;310(5745):43-5. No abstract available.

PMID:
16210515
9.

Personalized gene silencing therapeutics for Huntington disease.

Kay C, Skotte NH, Southwell AL, Hayden MR.

Clin Genet. 2014 Jul;86(1):29-36. doi: 10.1111/cge.12385. Epub 2014 Apr 11. Review.

PMID:
24646433
10.

Progress and challenges in RNA interference therapy for Huntington disease.

Harper SQ.

Arch Neurol. 2009 Aug;66(8):933-8. doi: 10.1001/archneurol.2009.180. Review. Erratum in: Arch Neurol. 2009 Oct;66(10):1272.

PMID:
19667213
11.

Experimental surgical therapies for Huntington's disease.

Demeestere J, Vandenberghe W.

CNS Neurosci Ther. 2011 Dec;17(6):705-13. doi: 10.1111/j.1755-5949.2010.00209.x. Epub 2010 Dec 28. Review.

PMID:
21199443
12.

Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.

Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR.

Nat Biotechnol. 2009 May;27(5):478-84. doi: 10.1038/nbt.1539. Epub 2009 May 3.

13.

Normal and mutant huntingtin: partners in crime.

Di Prospero NA, Tagle DA.

Nat Med. 2000 Nov;6(11):1208-9. No abstract available.

PMID:
11062523
14.

Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.

Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR.

Mol Ther. 2015 Nov;23(11):1759-1771. doi: 10.1038/mt.2015.128. Epub 2015 Jul 23.

15.

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL.

Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5820-5. Epub 2005 Apr 5.

16.

Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases.

Krainc D.

Arch Neurol. 2010 Apr;67(4):388-92. doi: 10.1001/archneurol.2010.40. Review.

PMID:
20385902
17.

Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.

Olson SD, Kambal A, Pollock K, Mitchell GM, Stewart H, Kalomoiris S, Cary W, Nacey C, Pepper K, Nolta JA.

Mol Cell Neurosci. 2012 Mar;49(3):271-81. doi: 10.1016/j.mcn.2011.12.001. Epub 2011 Dec 8.

18.

Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.

Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC.

J Med Genet. 2001 Jul;38(7):450-2.

19.

Mouse models of Huntington's disease.

Menalled LB, Chesselet MF.

Trends Pharmacol Sci. 2002 Jan;23(1):32-9. Review.

PMID:
11804649
20.

Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease.

Skogen M, Roth J, Yerkes S, Parekh-Olmedo H, Kmiec E.

BMC Neurosci. 2006 Oct 2;7:65.

Supplemental Content

Support Center